H.R. 119 prohibits any entity that receives federal funds under a specified set of COVID relief statutes from mandating that any of its employees receive a COVID‑19 vaccine. The bill lists six pandemic-era laws (including the CARES Act and the American Rescue Plan) and prescribes a single remedy: an entity that violates the prohibition “shall return any funds received” from the relevant COVID relief package.
This is a narrow statutory text with broad practical reach. If read expansively, the ban would reach state and local governments, hospitals, universities, nonprofits, private employers and contractors that obtained money under the listed Acts.
The bill is notable for using a funding condition and a clawback remedy rather than creating penalties or an administrative enforcement path, which creates a range of implementation questions for agencies, recipients, and counsel.
At a Glance
What It Does
The bill makes it unlawful for any recipient of funds distributed under six named COVID relief laws to impose a COVID‑19 vaccine mandate on employees, and it requires any violator to return funds tied to those relief packages to the federal government.
Who It Affects
Direct and indirect recipients of funds under the listed statutes — states, territories, tribes, local governments, hospitals, colleges, nonprofits, private employers and contractors that received CARES, PPP‑related funding, ARPA, or other enumerated relief monies — are within the bill’s scope.
Why It Matters
By conditioning the use of pandemic-era funds, the bill constrains a common federal lever for shaping workplace public‑health requirements and pivots enforcement to repayment risk. That raises urgent compliance, auditing, and legal‑interpretation issues for agencies and recipients that relied on those funds.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill contains a single substantive section with three parts. The core prohibition bars any entity that received funds under a listed COVID relief statute from requiring any of its employees to receive a COVID‑19 vaccine.
The text is categorical — it prohibits ‘‘mandat[ing] that any employee … receives a COVID‑19 vaccine’’ — but it does not define ‘‘mandate,’’ ‘‘employee,’’ or what it means to ‘‘receive’’ funds, which leaves several practical interpretive gaps.
The bill defines ‘‘COVID relief package’’ by naming six specific laws passed in 2020–2021 (for example, the CARES Act and the American Rescue Plan). That definition ties the statute’s reach to recipients of money traceable to those Acts, not to more recent appropriations or unrelated federal funding streams.
The remedy the bill prescribes for noncompliance is an instruction that any violator ‘‘shall return any funds received’’ from the relevant COVID relief package; the statute does not set a timetable, interest, recapture procedure, or designate an enforcing federal agency.Because the statute conditions a wide range of actors on receipt of specified funds, it could cover entities that received direct grant money as well as subrecipients that benefitted through state or local pass‑through programs. Similarly, the prohibition targets employer action (vaccine mandates) rather than incentives or logistics: the bill speaks only to mandates.
It therefore leaves open whether employer requirements tied to professional licensing, credentialing, or deployment (for example, hospital credential rules) are covered, and whether programs that require vaccination for program eligibility rather than employment would fall inside the ban.The bill’s sparse enforcement language is the critical operational problem. Without an identified agency to audit, enforce, or recover funds, implementation would likely fall to the departments that originally distributed the money (Treasury, HHS, SBA) or to appropriations/accounting offices that oversee federal grants.
Recipients and counsel will need to interpret the statute’s retroactivity, whether previously imposed mandates must be rescinded, how to calculate the amount to be returned where money has been spent, and whether administrative or judicial processes will mediate disputes. Those open questions are the principal compliance risks created by the bill’s current language.
The Five Things You Need to Know
The statute applies only to funds ‘‘received from a COVID relief package’’ and then lists six Acts by name, including the CARES Act and the American Rescue Plan Act of 2021.
It bars any entity that received such funds from ‘‘mandat[ing] that any employee … receives a COVID‑19 vaccine’’ but does not define key terms like ‘‘mandate,’’ ‘‘employee,’’ or ‘‘receive.’, The only remedy written into the bill is a mandatory return of funds: any entity in violation ‘‘shall return any funds received from the COVID relief package to the Federal Government.’, The bill contains no designated enforcement agency, no procedural timeline for repayment, and does not create a private right of action or criminal penalty.
The prohibition targets mandates specifically and does not address employer incentives, testing alternatives, or policies tied to licensure or safety rules, leaving those areas legally uncertain.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Funding‑condition ban on employee COVID‑19 vaccine mandates
This subsection imposes the substantive prohibition: entities that ‘‘receive Federal funds from a COVID relief package’’ may not require any of their employees to receive a COVID‑19 vaccine. Practically, that converts a roster of pandemic‑era appropriations and emergency laws into a crosscutting limitation on employer conduct. The provision’s brevity creates interpretive problems: it does not say whether the ban covers subrecipients, whether it applies to mandates imposed before receipt of funds, or whether an employer that received a very small, time‑limited payment is subject to the same constraint as a large government grantee.
Clawback remedy—return of funds for violators
Subsection (b) prescribes the sole statutory consequence: return of the funds received from the COVID relief package. The bill does not specify how agencies should calculate amounts to be repaid if funds have already been spent, whether repayment must include interest or penalties, or which agency will demand or collect the money. That creates practical enforcement reliance on agency guidance, interagency coordination, or litigation to determine procedure and scope.
Enumerated definition of 'COVID relief package'
This subsection defines the statutes whose funds trigger the prohibition by naming six pandemic-era laws (e.g., CARES Act, Families First, ARPA). By tying the restriction to those specific Acts, the bill excludes other federal funding streams not listed, but it imports complexity: many recipients received multiple types of pandemic relief, and funds often passed through states or localities. Determining whether a particular dollar is traceable to one of these Acts will be a necessary and potentially intricate auditing task.
This bill is one of many.
Codify tracks hundreds of bills on Employment across all five countries.
Explore Employment in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Employees who decline COVID‑19 vaccination: They would be protected from employer‑imposed vaccination requirements if their employer received funds under one of the named laws.
- Employers opposed to mandates: Employers that prefer not to impose vaccine mandates gain statutory cover to avoid mandatory vaccination policies without risking the loss of employee discipline claims tied to mandates.
- Organizations and advocacy groups that challenge vaccine mandates: Groups litigating or lobbying against mandates would gain a statutory basis for demanding rescission of vaccine requirements where recipients obtained the listed relief funds.
Who Bears the Cost
- Hospitals, health systems, and nursing homes that received pandemic relief: Those institutions may face the choice of rescinding vaccine requirements for staff or returning substantial federal funds, potentially exacerbating workforce and fiscal strain.
- State and local governments and school systems that took ARPA/CARES funds: These public entities risk having to unwind public‑health employment policies or contend with federal recoupment actions and auditing costs.
- Federal agencies (Treasury, HHS, SBA) and OMB: Agencies that administered the relief will likely need to interpret, audit, and potentially recover funds without prescribed procedures, increasing administrative burdens and litigation exposure.
Key Issues
The Core Tension
The bill pits two legitimate aims against each other: limiting federal leverage over employer public‑health decisions (protecting employee choice and curbing conditions tied to pandemic relief) versus preserving the federal government’s ability to condition emergency funds to promote public‑health protections. The choice between forbidding mandates via funding conditions and allowing agencies to continue using funds to encourage protective workplace rules has no straightforward legal or policy fix in this text — it simply shifts the choice into implementation and adjudication.
The bill’s mechanics hinge on interpretation and enforcement details the text does not provide. First, ‘‘receives Federal funds’’ is ambiguous: it can mean direct recipients, subrecipients, or any entity that benefitted indirectly via state pass‑through programs.
Auditors will need to trace funding streams to determine coverage, which is administratively intensive and fact‑specific. Second, the mandatory repayment remedy is blunt: if funds have been spent, agencies and courts will face disputes over whether full repayment is required, whether repayment should be prorated, and whether interest or penalties apply.
The statute is silent on administrative process, appeal rights, or equitable defenses.
The bill also leaves open critical definitional and scope questions that drive compliance risk. It does not define ‘‘mandate,’’ so employers and agencies must decide whether policies that require vaccination as a condition of certain duties (rather than blanket employment) are covered.
The text targets ‘‘employees’’ and not contractors or program participants, but many workplaces rely on contractors and volunteers — lines that will matter in sectoral application. Finally, the statute does not address interactions with existing federal requirements (for example, any CMS or grant‑conditioned health requirements) or state public‑health laws; resolving those conflicts would likely require agency rulemaking or litigation.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.